176 related articles for article (PubMed ID: 7514051)
1. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
Deisseroth AB; Zu Z; Claxton D; Hanania EG; Fu S; Ellerson D; Goldberg L; Thomas M; Janicek K; Anderson WF
Blood; 1994 May; 83(10):3068-76. PubMed ID: 7514051
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
Claxton D; Suh SP; Filaccio M; Ellerson D; Gaozza E; Andersson B; Brenner M; Reading C; Feinberg A; Moen R
Hum Gene Ther; 1991; 2(4):317-21. PubMed ID: 1665348
[TBL] [Abstract][Full Text] [Related]
3. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
[TBL] [Abstract][Full Text] [Related]
5. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
6. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
[TBL] [Abstract][Full Text] [Related]
7. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
8. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia.
Roth MS; Antin JH; Ash R; Terry VH; Gotlieb M; Silver SM; Ginsburg D
Blood; 1992 Jan; 79(1):276-82. PubMed ID: 1728316
[TBL] [Abstract][Full Text] [Related]
10. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
Verfaillie CM; Miller WJ; Boylan K; McGlave PB
Blood; 1992 Feb; 79(4):1003-10. PubMed ID: 1371077
[TBL] [Abstract][Full Text] [Related]
11. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Delage R; Soiffer RJ; Dear K; Ritz J
Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268
[TBL] [Abstract][Full Text] [Related]
13. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
[TBL] [Abstract][Full Text] [Related]
14. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
[TBL] [Abstract][Full Text] [Related]
15. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB
Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614
[TBL] [Abstract][Full Text] [Related]
17. Relapse in chronic myeloid leukemia after bone marrow transplantation: biomathematical modeling as a new approach to understanding pathogenesis.
Vincent PC; Rutzen-Loesevitz L; Tibken B; Heinze B; Hofer EP; Fliedner TM
Stem Cells; 1999; 17(1):9-17. PubMed ID: 10215403
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
19. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
20. Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Lange W; Herkert R; Finke J; Ragoczy U; Siegert W; Mertelsmann R; Dölken G
Ann Hematol; 1991 Oct; 63(4):189-94. PubMed ID: 1932296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
